GLP-1 drugs are revolutionizing the way people eat and spend their money, according to a recent survey. The findings reveal that approximately three million Canadian adults are currently taking GLP-1 drugs like Ozempic or Mounjaro, and many more are interested in doing so. However, cost remains a significant barrier for potential users. The survey, conducted by Leger Healthcare, highlights the impact of these medications on appetite and food cravings. Over half of the respondents reported a decreased appetite, and 40% mentioned reduced food cravings. As a result, GLP-1 users are making significant changes to their spending habits. Around 30% are eating out or ordering takeout less frequently, while a third are increasing their consumption of fresh fruits, vegetables, and protein-rich foods. Weight loss is the primary motivation for taking or considering GLP-1 medications, followed by diabetes management. Interestingly, more than half of those interested in the medication stated that insurance coverage or lower-cost generic options would influence their decision. The survey also explores the body positivity movement in the context of GLP-1 drugs. It suggests that the rise of these medications might impact the online body positivity movement, as people's dietary choices and behaviors change. Despite the potential benefits, the survey reveals that side effects are a concern. Gastrointestinal issues, such as nausea, vomiting, constipation, and diarrhea, are common. More severe complications, including gall bladder inflammation and pancreatitis, can occur, though most side effects are minor, according to doctors. The survey further highlights the financial burden of GLP-1 drugs. A quarter of respondents taking or considering these medications are paying for them out of pocket, which can be a significant monthly expense. In contrast, 28% have full coverage through private or public insurance plans, and almost half have partial insurance coverage. The survey was conducted online with 1,536 Canadians aged 18 and over from February 6 to 9, 2026, and the results suggest that the impact of GLP-1 drugs extends beyond prescription and into everyday shopping behaviors and health decisions.
